Plant-Made Nanobodies for Botulism Treatment
用于肉毒杆菌中毒治疗的植物制造纳米抗体
基本信息
- 批准号:8058704
- 负责人:
- 金额:$ 23.68万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2011
- 资助国家:美国
- 起止时间:2011-07-25 至 2013-06-30
- 项目状态:已结题
- 来源:
- 关键词:AffinityAmino Acid SequenceAntibodiesAntitoxinsBindingBiologicalBiological AssayBiotechnologyBontoxilysinBotulinum ToxinsBotulismCatalytic DomainCell membraneCellsCharacteristicsChimera organismCleaved cellCultured CellsCytosolDoseEndosomesEquus caballusEventExcisionGenesGoalsGrantHumanImmunoglobulin FragmentsImmunotherapyIn VitroInjectableLabelLaboratoriesLibrariesLightLlamaMechanical VentilatorsMetalloproteasesMonoclonal AntibodiesMotor NeuronsMusN-terminalNerveNeuronsParalysedPeptidesPhasePlanetsPlantsPoisoningProteinsRattusRecombinant ProteinsRecombinantsResearchResearch SupportS-nitro-N-acetylpenicillamineSerotypingSpinal CordSupportive careSymptomsSystemTechnologyTestingTherapeuticToxic effectToxicity TestsToxinWorkbasebotulism immune globulineffective therapyfluorophorein vivoneurotransmissionprotein aminoacid sequencepublic health prioritiesresearch studysuccessuptake
项目摘要
DESCRIPTION (provided by applicant): The ultimate goal of the research described in this application is to develop an economical, safe and effective therapeutic that can reverse the paralytic symptoms of botulism. Success in achieving this goal could save countless lives in the event of a bioterrorist attack by botulinum toxin. The goal of administering an anti-toxin antibody is rapid and complete removal of the toxin from the body. Currently available immunotherapies for botulism (equine antitoxin, human botulism immune globulin, monoclonal antibodies) can remove only toxin molecules that have not yet reached motor neurons. Once the catalytic light chain of the toxin reaches the cytosol of motor neurons, where it cleaves proteins involved in neurotransmission, it is inaccessible to normal antibodies. This is why victims of botulinum neurotoxin poisoning may need supportive care on a respirator for many weeks. We propose using a new single-chain variable fragment, a nanobody, against the catalytic site of the toxin light chain, along with technology that allows proteins to penetrate into the cytosol of motor neurons, to reverse the paralysis caused by the toxin. We will start with a single-domain variable fragment, isolated from a llama antibody library in the laboratory of our collaborator, Dr James Marks (UCSF), that inhibits the ability of the toxin light chain to cleave it's protein substrate. We will express fusions of this nanobody to various cell-penetrating peptides, using a plant expression system. We will then test the ability of these nanobody fusions to enter primary rat neuron cells and inhibit toxin activity. Finally, we will test the toxicity of the cell-penetrating nanobody in mice.
PUBLIC HEALTH RELEVANCE: Botulinum toxin is the deadliest biological substance known, and would be easy for a terrorist to produce and use to cause large numbers of casualties. This makes developing an effective and economical countermeasure to protect the public a public health priority. The research supported by this grant will lay the groundwork for using plants to produce a highly protective, safe and economical antitoxin therapy.
描述(由申请人提供):本申请中描述的研究的最终目标是开发一种经济,安全和有效的治疗方法,可以逆转肉毒杆菌中毒的麻痹症状。如果成功实现这一目标,就可以在肉毒杆菌毒素生物恐怖袭击中挽救无数生命。施用抗毒素抗体的目的是快速且完全地从体内去除毒素。目前可用的肉毒中毒免疫疗法(马抗毒素,人肉毒中毒免疫球蛋白,单克隆抗体)只能清除尚未到达运动神经元的毒素分子。一旦毒素的催化轻链到达运动神经元的胞质溶胶,在那里它切割参与神经传递的蛋白质,正常抗体就无法接近它。这就是为什么肉毒杆菌神经毒素中毒的受害者可能需要在呼吸器上进行数周的支持性护理。我们建议使用一种新的单链可变片段,一种纳米抗体,对抗毒素轻链的催化位点,沿着技术,使蛋白质渗透到运动神经元的胞质中,以逆转毒素引起的瘫痪。我们将从我们的合作者James Marks博士(UCSF)实验室的美洲驼抗体库中分离出的单域可变片段开始,该片段抑制毒素轻链切割其蛋白质底物的能力。我们将使用植物表达系统表达这种纳米抗体与各种细胞穿透肽的融合体。然后,我们将测试这些纳米抗体融合物进入原代大鼠神经元细胞并抑制毒素活性的能力。最后,我们将在小鼠中测试细胞穿透纳米抗体的毒性。
公共卫生关系:肉毒杆菌毒素是已知的最致命的生物物质,恐怖分子很容易生产和使用,造成大量伤亡。这使得制定有效和经济的对策来保护公众成为公共卫生的优先事项。这项资助支持的研究将为利用植物生产高度保护性,安全和经济的抗毒素疗法奠定基础。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
KEITH WYCOFF其他文献
KEITH WYCOFF的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('KEITH WYCOFF', 18)}}的其他基金
Factor H Fc fusions as novel therapeutics for Burkholderia pseudomallei infections
H 因子 Fc 融合作为鼻疽伯克霍尔德杆菌感染的新疗法
- 批准号:
10766626 - 财政年份:2023
- 资助金额:
$ 23.68万 - 项目类别:
FH-Fc as a Pre-Exposure Prophylactic for Tickborne Disease
FH-Fc 作为蜱传疾病的暴露前预防剂
- 批准号:
10219129 - 财政年份:2020
- 资助金额:
$ 23.68万 - 项目类别:
Improving gene expression via Massively Parallel Synonymous Codon Variant Screening
通过大规模并行同义密码子变体筛选提高基因表达
- 批准号:
9908223 - 财政年份:2020
- 资助金额:
$ 23.68万 - 项目类别:
FH-Fc as a Pre-Exposure Prophylactic for Tickborne Disease
FH-Fc 作为蜱传疾病的暴露前预防剂
- 批准号:
10082224 - 财政年份:2020
- 资助金额:
$ 23.68万 - 项目类别:
A mucosally targeted MERS-CoV vaccine produced in plants
在植物中生产的粘膜靶向 MERS-CoV 疫苗
- 批准号:
9141182 - 财政年份:2017
- 资助金额:
$ 23.68万 - 项目类别:
Exploiting Superinfection Exclusion To Express Polyclonal Antibodies In Plants
利用重复感染排除在植物中表达多克隆抗体
- 批准号:
8781667 - 财政年份:2014
- 资助金额:
$ 23.68万 - 项目类别:
Targeted mutagenesis of plant genes by the CRISPR/Cas system
CRISPR/Cas系统对植物基因进行定点突变
- 批准号:
8713873 - 财政年份:2014
- 资助金额:
$ 23.68万 - 项目类别:
相似海外基金
Cerebral infarction treatment strategy using collagen-like "triple helix peptide" containing functional amino acid sequence
含功能氨基酸序列的类胶原“三螺旋肽”治疗脑梗塞策略
- 批准号:
23K06972 - 财政年份:2023
- 资助金额:
$ 23.68万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Establishment of a screening method for functional microproteins independent of amino acid sequence conservation
不依赖氨基酸序列保守性的功能性微生物蛋白筛选方法的建立
- 批准号:
23KJ0939 - 财政年份:2023
- 资助金额:
$ 23.68万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Effects of amino acid sequence and lipids on the structure and self-association of transmembrane helices
氨基酸序列和脂质对跨膜螺旋结构和自缔合的影响
- 批准号:
19K07013 - 财政年份:2019
- 资助金额:
$ 23.68万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Construction of electron-transfer amino acid sequence probe with an interaction for protein and cell
蛋白质与细胞相互作用的电子转移氨基酸序列探针的构建
- 批准号:
16K05820 - 财政年份:2016
- 资助金额:
$ 23.68万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Development of artificial antibody of anti-bitter taste receptor using random amino acid sequence library
利用随机氨基酸序列库开发抗苦味受体人工抗体
- 批准号:
16K08426 - 财政年份:2016
- 资助金额:
$ 23.68万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
The aa15-17 amino acid sequence in the terminal protein domain of HBV polymerase as a viral factor affect-ing in vivo as well as in vitro replication activity of the virus.
HBV聚合酶末端蛋白结构域中的aa15-17氨基酸序列作为影响病毒体内和体外复制活性的病毒因子。
- 批准号:
25461010 - 财政年份:2013
- 资助金额:
$ 23.68万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Amino acid sequence analysis of fossil proteins using mass spectrometry
使用质谱法分析化石蛋白质的氨基酸序列
- 批准号:
23654177 - 财政年份:2011
- 资助金额:
$ 23.68万 - 项目类别:
Grant-in-Aid for Challenging Exploratory Research
Precise hybrid synthesis of glycoprotein through amino acid sequence-specific introduction of oligosaccharide followed by enzymatic transglycosylation reaction
通过氨基酸序列特异性引入寡糖,然后进行酶促糖基转移反应,精确杂合合成糖蛋白
- 批准号:
22550105 - 财政年份:2010
- 资助金额:
$ 23.68万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Estimating selection on amino-acid sequence polymorphisms in Drosophila
果蝇氨基酸序列多态性选择的估计
- 批准号:
NE/D00232X/1 - 财政年份:2006
- 资助金额:
$ 23.68万 - 项目类别:
Research Grant
Construction of a neural network for detecting novel domains from amino acid sequence information only
构建仅从氨基酸序列信息检测新结构域的神经网络
- 批准号:
16500189 - 财政年份:2004
- 资助金额:
$ 23.68万 - 项目类别:
Grant-in-Aid for Scientific Research (C)